Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.42 |
| ▸ | BID | P55957 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490489 | 0.89 | MEN1 (0.43) | — | |
| SCHEMBL6484182 | 0.88 | MMP1 (0.50) | MAPTGAAHTTTACR1MMP1 | |
| SCHEMBL6482403 | 0.88 | HDAC6 (0.43) | MAPTGAAHTTTACR1MMP1 | |
| SCHEMBL8790279 | 0.85 | MAPT (0.46) | MAPTGAAHTTTACR1MMP1 | |
| SCHEMBL6491342 | 0.84 | GHSR (0.53) | MAPTGAAHTTTACR1MMP2 | |
| SCHEMBL8792189 | 0.84 | GHSR (0.53) | MAPTGAAHTTTACR1MMP2 | |
| SCHEMBL6482170 | 0.84 | SIRT2 (0.38) | HDAC1CTSL | |
| SCHEMBL8790632 | 0.82 | MMP2 (0.44) | MAPTGAAHTTTACR1MMP1 | |
| SCHEMBL8790623 | 0.82 | MMP2 (0.44) | MAPTGAAHTTTACR1MMP1 | |
| SCHEMBL6481453 | 0.81 | CTSS (0.38) | MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | MAPT 1178/4885GAA 54/4885HTT 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.